EP3784241A4 - Tricyclic heterocycle compounds useful as hiv integrase inhibitors - Google Patents
Tricyclic heterocycle compounds useful as hiv integrase inhibitors Download PDFInfo
- Publication number
- EP3784241A4 EP3784241A4 EP19793407.8A EP19793407A EP3784241A4 EP 3784241 A4 EP3784241 A4 EP 3784241A4 EP 19793407 A EP19793407 A EP 19793407A EP 3784241 A4 EP3784241 A4 EP 3784241A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compounds useful
- hiv integrase
- integrase inhibitors
- tricyclic heterocycle
- heterocycle compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862663377P | 2018-04-27 | 2018-04-27 | |
US201862664527P | 2018-04-30 | 2018-04-30 | |
PCT/US2019/028432 WO2019209667A1 (en) | 2018-04-27 | 2019-04-22 | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3784241A1 EP3784241A1 (en) | 2021-03-03 |
EP3784241A4 true EP3784241A4 (en) | 2022-01-19 |
Family
ID=68294232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19793407.8A Withdrawn EP3784241A4 (en) | 2018-04-27 | 2019-04-22 | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3784241A4 (en) |
JP (1) | JP2021522254A (en) |
KR (1) | KR20210005139A (en) |
CN (1) | CN112088005A (en) |
AU (1) | AU2019260608A1 (en) |
BR (1) | BR112020021768A2 (en) |
CA (1) | CA3101180A1 (en) |
MA (1) | MA52367A (en) |
MX (1) | MX2020011317A (en) |
WO (1) | WO2019209667A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202011386QA (en) | 2018-05-31 | 2020-12-30 | Shionogi & Co | Polycyclic pyridone derivative |
AR115455A1 (en) | 2018-05-31 | 2021-01-20 | Shionogi & Co | POLYCLIC PYRIDOTRIAZINE DERIVATIVE |
EP3801543B1 (en) | 2018-06-05 | 2024-09-11 | Merck Sharp & Dohme LLC | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
TWI745900B (en) | 2019-03-22 | 2021-11-11 | 美商基利科學股份有限公司 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
AU2020391106B2 (en) * | 2019-11-26 | 2024-03-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
PE20221569A1 (en) * | 2020-02-24 | 2022-10-06 | Gilead Sciences Inc | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS |
ES2968058T3 (en) | 2021-01-19 | 2024-05-07 | Gilead Sciences Inc | Substituted pyridotriazine compounds and uses thereof |
TWI843506B (en) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014183532A1 (en) * | 2013-05-17 | 2014-11-20 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
WO2017113288A1 (en) * | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002334205B2 (en) * | 2001-10-26 | 2007-07-05 | Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase |
TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
US7902182B2 (en) * | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
-
2019
- 2019-04-22 CA CA3101180A patent/CA3101180A1/en active Pending
- 2019-04-22 BR BR112020021768-9A patent/BR112020021768A2/en not_active Application Discontinuation
- 2019-04-22 AU AU2019260608A patent/AU2019260608A1/en not_active Abandoned
- 2019-04-22 MA MA052367A patent/MA52367A/en unknown
- 2019-04-22 EP EP19793407.8A patent/EP3784241A4/en not_active Withdrawn
- 2019-04-22 MX MX2020011317A patent/MX2020011317A/en unknown
- 2019-04-22 JP JP2020559525A patent/JP2021522254A/en active Pending
- 2019-04-22 KR KR1020207033726A patent/KR20210005139A/en unknown
- 2019-04-22 CN CN201980028504.5A patent/CN112088005A/en active Pending
- 2019-04-22 WO PCT/US2019/028432 patent/WO2019209667A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014183532A1 (en) * | 2013-05-17 | 2014-11-20 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
WO2017113288A1 (en) * | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
Non-Patent Citations (2)
Title |
---|
See also references of WO2019209667A1 * |
ZUO XIAOFANG ET AL: "Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017)", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 28, no. 4, 3 April 2018 (2018-04-03), GB, pages 299 - 316, XP055870040, ISSN: 1354-3776, Retrieved from the Internet <URL:http://dx.doi.org/10.1080/13543776.2018.1438410> DOI: 10.1080/13543776.2018.1438410 * |
Also Published As
Publication number | Publication date |
---|---|
MX2020011317A (en) | 2020-11-18 |
EP3784241A1 (en) | 2021-03-03 |
WO2019209667A1 (en) | 2019-10-31 |
JP2021522254A (en) | 2021-08-30 |
AU2019260608A1 (en) | 2020-10-29 |
KR20210005139A (en) | 2021-01-13 |
BR112020021768A2 (en) | 2021-01-26 |
MA52367A (en) | 2021-03-03 |
CN112088005A (en) | 2020-12-15 |
CA3101180A1 (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3752144A4 (en) | Tricyclic heterocycle compounds useful as hiv integrase inhibitors | |
EP3784241A4 (en) | Tricyclic heterocycle compounds useful as hiv integrase inhibitors | |
EP3801543A4 (en) | Tricyclic heterocycle compounds useful as hiv integrase inhibitors | |
EP3548031A4 (en) | Tricyclic heterocycle compounds useful as hiv integrase inhibitors | |
IL266908A (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
EP3827009A4 (en) | Heterobicyclic compounds for inhibiting the activity of shp2 | |
EP3229805A4 (en) | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors | |
EP3229804A4 (en) | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors | |
EP3464272A4 (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
EP3285582A4 (en) | Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors | |
TWI800498B (en) | Bicyclic dihydropyrimidine-carboxamide derivatives as rho-kinase inhibitors | |
EP3083641A4 (en) | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors | |
EP3377065A4 (en) | Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors | |
EP3377066A4 (en) | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors | |
EP3402799A4 (en) | Heterocyclic compounds as rsv inhibitors | |
EP3389380A4 (en) | Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors | |
EP3049081A4 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors | |
EP3008044A4 (en) | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors | |
EP3978503A4 (en) | ANNELATED 9-HYDROXY-1,8-DIOXO-1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-a]PYRAZINE-7-CARBOXAMIDES AS HIV INTEGRASE INHIBITORS | |
EP3303341A4 (en) | Fused tricyclic heterocyclic compounds useful for treating hiv infection | |
EP3573984A4 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors | |
EP3822276A4 (en) | Heterocyclic compound as trk inhibitor | |
EP3774812A4 (en) | Macrocyclic compounds as trk kinases inhibitors | |
EP3753926A4 (en) | Spiro compound as indoleamine-2,3-dioxygenase inhibitor | |
EP3558305A4 (en) | Heterocyclic compounds as hiv protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20201127 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RAV | Requested validation state of the european patent: fee paid |
Extension state: MA Effective date: 20201127 Extension state: MD Effective date: 20201127 Extension state: TN Effective date: 20201127 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20211216 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 487/16 20060101ALI20211210BHEP Ipc: A61K 31/4985 20060101AFI20211210BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MERCK SHARP & DOHME LLC |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20230208 |